Health Condition 1: N209- Urinary calculus, unspecified
Conditions
Interventions
Intervention1: Dapagliflozin 10 mg: dose of Dapagliflozin: 10 MG
frequency: Once daily
route of administration: oral total duration: 6 months
Control Intervention1: Placebo: dose of placebo: empty t
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with known renal stone disease, after getting stone clearance by either medical expulsive therapy or by endoscopic surgery, Age between 18 to 60 years, Renal stones of the following types: Calcium phosphate, Calcium Oxalate, Uric acid.
Exclusion criteria
Exclusion criteria: Exclusion criteria: Recurrent stone formers with confirmed alternate diagnoses such as incomplete RTA, Bartter s, cystinuria, history of surgery in prior 6 weeks, Dehydration, Hemodynamic instability, Critical illness, Lower urinary tract symptoms, Severe renal failure with eGFR less than 45 ml per min, Patient on any SGLT2 inhibitors at the time of enrolment or in previous 3 months, Patient on teriparatide, bisphosphonates, denosumab at the time of enrolment or in previous 6 months, Sepsis or septic shock, Moribund patients with reduced life expectancy, Severe cardiopulmonary disease, Pregnancy and lactation, History of genital infections or urinary tract infections, Primary Hyperparathyroidism, Malignancy, Congenital anomaly of kidney and urinary tract
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in urinary super saturation in the study groups, urinary markers of inflammation and incidence of new stone formationTimepoint: Baseline and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: nil | — |
Countries
India
Contacts
Public ContactVipin Chandra
All india institute of Medical sciences, patna
Outcome results
None listed